{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T16:15:44Z","timestamp":1648829744981},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11096-020-01214-x","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T13:04:53Z","timestamp":1610024693000},"page":"1149-1151","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Answers to the authors of the \u201cLetter to the Editor\u201d: A comparative study between non colistin based combinations\nfor treatment of infections caused by extensive drug resistant Acinetobacter baumannii: comments"],"prefix":"10.1007","volume":"43","author":[{"given":"Mohamed Ahmed","family":"Elarabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"6","key":"1214_CR1","first-page":"1369","volume":"61","author":"MS Oliveira","year":"2008","unstructured":"Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin\/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacterspp. J AntimicrobChemother. 2008;61(6):1369\u201375.","journal-title":"J AntimicrobChemother"},{"key":"1214_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12879-016-1717-6","volume":"16","author":"JJ Ye","year":"2016","unstructured":"Ye JJ, Lin HS, Yeh CF, et al. Tigecycline-based versus sulbactam based treatment for pneumonia involving multidrug-resistant Acinetobactercalcoaceticus-Acinetobacterbaumannii complex. BMC Infect Dis. 2016;16:374.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1214_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","volume":"21","author":"SY Jung","year":"2017","unstructured":"Jung SY, Lee SH, Lee SY, Yang S, Noh H, Chung EK, Lee JI. Antimicrobials for the treatment of drug-resistant Acinetobacterbaumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care. 2017;21(1):319.","journal-title":"Crit Care"},{"key":"1214_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2334-14-102","volume":"14","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline- based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacterbaumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1214_CR5","doi-asserted-by":"publisher","first-page":"e0150642","DOI":"10.1371\/journal.pone.0150642","volume":"11","author":"WY Kim","year":"2016","unstructured":"Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, Chong YP, Hong SB. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacterbaumannii pneumonia in critically ill patients. PLoS ONE. 2016;11(3):e0150642.","journal-title":"PLoS ONE"},{"key":"1214_CR6","unstructured":"Zeina A, Kanafani M, Souha S, Kanj MD. Acinetobacter infection: treatment and prevention. UpToDate: Wolters Kluwer Clinical Drug Information, Inc., 2018. Retrieved 21 March 2018, from https:\/\/www.uptodate.com\/contents\/acinetobacter-infection treatment-and-prevention."},{"key":"1214_CR7","unstructured":"Antibiotic name. Lexicomp Online, Lexi-drugs online: Wolters Kluwer Clinical Drug Information, Inc., 2018.Available from: http:\/\/online.lexi.com. Subscription required to view."},{"issue":"1","key":"1214_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/653120","volume":"51","author":"J Fishbain","year":"2010","unstructured":"Fishbain J, Peleg AY. Treatment of Acinetobacter Infections. Clin Infect Dis. 2010;51(1):79\u201384. https:\/\/doi.org\/10.1086\/653120.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1214_CR9","first-page":"120","volume":"56","author":"Y Qin","year":"2018","unstructured":"Qin Y, Zhang J, Wu L, Zhang D, Fu L, Xue X. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator associated pneumonia caused by extensively drug-resistant Acinetobacterbaumannii. Int J ClinPharmacolTher. 2018;56(3):120\u20139.","journal-title":"Int J ClinPharmacolTher"},{"issue":"1","key":"1214_CR10","first-page":"11","volume":"27","author":"SF Assimakopoulos","year":"2019","unstructured":"Assimakopoulos SF, Karamouzos V, Lefkaditi A, et al. Triple combination therapy with high-dose ampicillin\/sulbactam, high dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacterbaumannii: a case series study. Infez Med. 2019;27(1):11\u20136.","journal-title":"Infez Med"},{"issue":"5","key":"1214_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1179\/1973947814Y.0000000203","volume":"27","author":"B Liu","year":"2015","unstructured":"Liu B, Bai Y, Liu Y, et al. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacterbaumannii. J Chemother. 2015;27(5):271\u20136.","journal-title":"J Chemother"},{"issue":"4","key":"1214_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1590\/S1517-838246420140101","volume":"46","author":"F Temocin","year":"2015","unstructured":"Temocin F, Erdinc FS, Tulek N, et al. Synergistic effects of sulbactam in multi-drug-resistant Acinetobacterbaumannii. Braz J Microbiol. 2015;46(4):1119\u201324.","journal-title":"Braz J Microbiol"},{"issue":"9","key":"1214_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ja.2014.99","volume":"67","author":"X Dong","year":"2014","unstructured":"Dong X, Chen F, Zhang Y, Liu H, Liu Y, Ma L. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter. J Antibiot. 2014;67(9):677\u201380.","journal-title":"J Antibiot"},{"key":"1214_CR14","unstructured":"TYGACIL\u00ae (TIGECYCLINE) FOR INJECTION [Internet]. Accessdata.fda.gov. 2010 [cited 24 August 2020]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021821s010lbl.pdf"},{"key":"1214_CR15","unstructured":"CLINICAL PHARMACOLOGY & BIOPHARMACEUTICS REVIEW of Tigecycline (Tygacil\u2122) [Internet]. Accessdata.fda.gov. 2005 [cited 24 August 2020]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021821Orig1s000ClinPharmR.pdf"},{"key":"1214_CR16","unstructured":"SUMMARY OF PRODUCT CHARACTERISTICS of Tygacil 50 mg powder for solution for infusion [Internet]. Ema.europa.eu. [cited 24 August 2020]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tygacil-epar-product-information_en.pdf"},{"key":"1214_CR17","unstructured":"Tigecycline 50 mg powder for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Medicines.org.uk. 2018 [cited 24 August 2020]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/9232\/smpc"},{"key":"1214_CR18","unstructured":"Moehring R, J Anderson D. Gram-negative bacillary bacteremia in adults [Internet]. Uptodate.com. 2020 [cited 24 August 2020]. Available from: https:\/\/www.uptodate.com\/contents\/gram-negative-bacillary-bacteremia-in-adults#H13"},{"key":"1214_CR19","unstructured":"UNASYN\u00ae (ampicillin sodium\/sulbactam sodium) [Internet]. Accessdata.fda.gov. 2017 [cited 24 August 2020]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050608s044lbl.pdf"},{"issue":"(Supplement_5)","key":"1214_CR20","doi-asserted-by":"publisher","first-page":"S503","DOI":"10.1093\/clinids\/8.Supplement_5.503","volume":"8","author":"G Foulds","year":"1986","unstructured":"Foulds G. Pharmacokinetics of sulbactam\/ampicillin in humans: a review. Rev Infect Dis. 1986;8((Supplement_5)):S503\u201311.","journal-title":"Rev Infect Dis"},{"issue":"5","key":"1214_CR21","first-page":"1613","volume":"47","author":"BA Cunha","year":"2009","unstructured":"Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiellapneumoniae or MDR Acinetobacterbaumanniiurosepsis. J ClinMicrobiol. 2009;47(5):1613.","journal-title":"J ClinMicrobiol"},{"issue":"7","key":"1214_CR22","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s00134-017-4802-4","volume":"43","author":"JF Timsit","year":"2017","unstructured":"Timsit JF, de Kraker ME, Sommer H, Weiss E, Bettiol E, Wolkewitz M, Nikolakopoulos S, Wilson D, Harbarth S. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE\u2019s STAT-Net. Intensive Care Med. 2017;43(7):1002\u201312.","journal-title":"Intensive Care Med"},{"key":"1214_CR23","unstructured":"Malone M. Chapter 3 - The Microbiome of Diabetic Foot Ulcers and the Role of Biofilms [Internet]. sciencedirect. 2020 [cited 12 December 2020]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780128110799000033?via%3Dihub."},{"key":"1214_CR24","unstructured":"Marston W. Chapter 20 - Venous Ulcers [Internet]. Atlas of Endovascular Venous Surgery Book, 2nd Edition. 2019 [cited 3 September 2020]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780323511391000206"},{"issue":"5","key":"1214_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ijantimicag.2014.06.014","volume":"44","author":"P Piewngam","year":"2014","unstructured":"Piewngam P, Kiratisin P. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacterbaumannii clinical isolates, including multidrug-resistant isolates. Int J Antimicrob Agents. 2014;44(5):396\u2013401.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1214_CR26","first-page":"81","volume":"38","author":"M \u015eim\u015fek","year":"2020","unstructured":"\u015eim\u015fek M, Demir C. Determination of Colistin and Tigecycline Resistance Profile of AcinetobacterBaumannii Strains from Different Clinical Samples in a Territory Hospital in Turkey. J Health Sci Med Res. 2020;38(2):81\u201391.","journal-title":"J Health Sci Med Res"},{"issue":"5","key":"1214_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1179\/1973947814Y.0000000193","volume":"27","author":"A Spiliopoulou","year":"2015","unstructured":"Spiliopoulou A, Jelastopulu E, Vamvakopoulou S, Bartzavali C, Kolonitsiou F, Anastassiou ED, Christofidou M. In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period. J Chemother. 2015;27(5):266\u201370.","journal-title":"J Chemother"},{"issue":"8","key":"1214_CR28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cmi.2019.05.004","volume":"25","author":"M Paul","year":"2019","unstructured":"Paul M, Scudeller L. Clinical research designs to study treatment effects for multidrug-resistant bacteria. ClinMicrobiol Infect. 2019;25(8):929\u201331.","journal-title":"ClinMicrobiol Infect"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01214-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:29:49Z","timestamp":1628537389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01214-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01214-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"7 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}